

IS THE BIOPHARMA INDUSTRY SUSTAINABLE?

How partnering can help address geopolitical,
environmental and pricing challenges



Swiss HLG Conference

7th- 9th May, 2023

Grand Hotel Suisse Majestic, Montreux

www.swisshlg.com

WE THANK THE SUPPORTERS OF SWISS HLG 2023

Platinum:



Gold:



Silver:



Bronze:



WELCOME TO THE SWISS HEALTHCARE LICENSING GROUP!

Building relationships for a better healthcare environment

Swiss HLG is an association of Healthcare Executives focusing on Business Development and Partnering with the shared objective to provide a unique and inspiring environment for professional development, sharing best practices and building business relationships.

Swiss HLG is open to the international healthcare and life sciences industries and has over 190 active members, mainly based in Switzerland but also Austria, France, Germany, Italy, Ireland, Netherlands, Monaco, Slovenia, South Korea, UK and USA.

The association is led by a volunteer Board which organizes conferences and delivers key initiatives. We have delivered 33 conferences with an excellent national and international reputation for quality, that offer great opportunities for networking, education, and business development.

Our initiatives aim to bring value to our members and the innovation ecosystem. They include educational webinars, networking events, developing and communicating Good Partnering Practices, a LinkedIn community and the Start-Up Initiative. Please join us!

Here's a brief summary of what membership benefits include:

- Focused and effective networking with senior level peers
- Opportunity to contribute to events, the Start-up Initiative, Good Partnering Practices (GPP) and other activities
- Education among peers and dissemination of GPPs
- Membership of our LinkedIn community
- Access to the unique PLG/HLG European database, encompassing members of an international network of 10 healthcare licensing groups
- Special rates and discounts to Swiss HLG & PLG /HLG joint events
- Increased visibility of your organization

Visit us at www.swisshlg.com

WELCOME TO OUR 34TH SWISS HLG CONFERENCE

Dear Members and Friends of the Swiss HLG

We are very happy and excited to meet face to face once again and give you the opportunity to network on the shore of Lake Geneva.

Our theme this year is the challenging question “*Is the biopharma industry sustainable?*” which we address through different lenses and always with a partnering mindset.

We have two eminent Keynote speakers on Sunday evening. The conference will be opened by an exciting presentation from Andy Wilkins, the Founder of Future of Health, sharing a vision for the future of healthcare in the 21st century. Andy's talk will be followed by a Keynote from Richard Bergstrom, Former EFPIA Director General and now Vice President European Affairs at IQVIA, giving his perspective on European health policy.

Our first session on Monday focuses on pricing and affordability and the role of partnering to help address challenges and benefit society. Spiralling R&D costs combined with a focus on delivering transformational outcomes for smaller patient populations with high unmet need conditions has driven higher prices. At the same time healthcare systems struggle with tremendous cost pressures. Three impressive and inspiring market access thought leaders will help us rethink our approach to our key stakeholders.

Our second session looks at emerging and broken business models and asks whether partnering can offer solutions. Expert speakers will look at curative cell and gene therapies, what the biopharma commercial model can learn from rare disease, and the promise and challenge of digital health. We finish the day with a thought-provoking Keynote from Brian Finrow, CEO and Founder of Lumen Bioscience, who will share how modelling the decline in R&D productivity can pinpoint key levers to reverse the trend.

Our final session turns the lens on how partnering enables the industry to adapt to a changing and fragmenting world. Here we look at ensuring the sustainability of our supply chains and the role of partnering to ensure preparedness for and respond to global pandemics. We finish the conference with a Closing Keynote from Lutz Hegemann, President Global Health & Sustainability at Novartis, who will provide an overview on what biopharma sustainability looks like, where companies can create the greatest impact, and the pivotal role that partnerships can play in driving this.

Please enjoy the opportunity to develop your business, share insights, learn and network in this beautiful location. We look forward to welcoming you personally in Montreux and seeing you again at our future events.

As current President of the association, I would like to acknowledge and thank our supporters and presenters for their contribution to the success of this meeting. Please also join me in thanking our Conference Directors Francesca and Ragip, our Board members, Organizers and Odelle for putting together the conference program with enthusiasm and commitment.

With warm regards



Sarah Holland
President, Swiss HLG



Francesca Lianza
Conference Co-Director 2023
Board Member, Swiss HLG



Ragip Ziyal
Conference Co-Director 2023
Board Member, Swiss HLG

PROGRAM

Sunday, May 7th 2023

15.30 onwards	Registration start – Check-in
16.00 – 17.00	Welcome Coffee & Networking
17.00 – 17.15	Welcome and opening of the Swiss HLG Conference 2023 Sarah Holland, President Swiss HLG
17.15 – 18.00	Key Note The Future of Healthcare in the 21st Century Andy Wilkins, Founder of FUTURE OF HEALTH
18.00 – 18.45	Key Note European Health Policy: what is Brussel up to? Richard Bergström, Former EFPIA Director General, Vice President European Affairs at IQVIA
18.45 – 19.00	Ice-breaker Chris Isler and Tytus Litynski, Swiss HLG Board Members
19.30 – 21.15	Kick-off Dinner
21.15 onwards	Networking with peers - Meet at the bar

Monday, May 8th 2023

The conference starts at 09.00

07.00	Pre-conference morning run & walk group - voluntary (meet at reception)
08.30 – 09.00	Swiss HLG General Assembly – Members by invitation
09.00 – 09.10	Welcome & Housekeeping <i>Intro - Pricing and affordability: The role of partnering to help address challenges and benefit society</i> Christoph Sarry, Swiss HLG Board Member
09.10 – 09.45	Emerging from Disruption: Rethinking Pharma Michael Oberreiter, Head of Global Access at Roche
09.45 – 10.20	Market access: moving from an adversarial to a collaborative relationship with healthcare systems Neil Grubert, Independent Global Market Access Consultant, Trainer & Writer
10.20 – 10.35	Group Photo
10.35 – 11.05	Refreshment Break & Networking

Monday, May 8th 2023, continued

11.05 – 11.40	Quo vadis, access? A perspective from regulators and payers Susanne Weissbäcker, Partner at EY-Parthenon, Strategy Life Sciences
11.40 – 12.10	Q&A and Panel - Michael Oberreiter, Neil Grubert and Susanne Weissbäcker Moderator - Luis Vieira, Swiss HLG Board Member
12.10 – 12.20	Wrap up of the morning/housekeeping Luis Vieira, Swiss HLG Board Member
12.20 – 13.45	Lunch & Networking
13.45 – 13.50	<i>Intro - Emerging and broken business models: Can partnering offer solutions?</i> Chris Isler, Swiss HLG Board Member
13.50 – 14.25	The promise of cell & gene therapies – is the European healthcare system equipped to fairly value and pay for one-time, potentially curative treatments Oswald Bentinck VP, Global Head - Value and Access at Rocket Pharmaceuticals
14.25 – 15.00	The partnering mindset: An essential shift to create more sustainable healthcare? Anne Njis, Transformation Lead Rare Conditions at Roche
15.00 – 15.30	Refreshment Break & Networking
15.30 – 16.05	Digital Health- friend or foe? What are we scared of? Chris Easton, Disease Area Stronghold Global Commercial Leader, Pulmonary Hypertension at Johnson & Johnson (Janssen Pharmaceuticals)
16.05 – 16.50	Monday Closing Key Note The sustainability of biopharma R&D productivity: Is 2023 the “perfect storm”? Brian Finrow, CEO and co-founder of Lumen Bioscience
16.50 – 17.00	Wrap up of the day Relaunch of Swiss HLG Start-Up Initiative Michael Huebner, Swiss HLG Board Member
18.15 onwards	Swiss HLG Gala Dinner in the beautiful medieval castle Château de Chillon Dress code business casual 18.15 meet at the entrance to the reception
22.15 onwards	Networking with peers Meet at the bar

PROGRAM

Tuesday, May 10th 2023

The conference starts at 09.15

07.30	Pre-conference morning run & walk group - voluntary (meet at reception)
09.15 – 09.20	Welcome & Housekeeping <i>Intro - How partnering enables the pharmaceutical sector to adapt to a changing and fragmenting world</i> Laurence de Schoulepnikoff, Swiss HLG Board Member
09.20 – 10.00	Current trends in life science/pharmaceutical industry supply chain.... Are changes accelerating in manufacturing? Jean Vielle, Global Head Integration Separation at Novartis AG The Global
10:00 –10.40	The Global Fight against the Big Pandemics: A case study on Partnerships, Sustainability and Innovation Lelio Marmora, CEO at The Management Lab
10.40– 11.10	Refreshment Break & Networking
11.10 – 11.50	Closing Key Note Sustainability in the biopharma industry: how partnerships can drive impact Lutz Hegemann, President Global Health & Sustainability at Novartis
11.50 – 12.00	Closing Remarks Jean-Marc Séquier, Vice President Swiss HLG
12.00 - 13.30	Farewell Lunch



**BECOME A MEMBER / BECOME A SUPPORTER
WE ARE ONLY AS STRONG AS OUR MEMBERS**

www.swisshlg.com



KEY NOTE

THE FUTURE OF HEALTHCARE IN THE 21ST CENTURY

Abstract

We are standing at the dawn of the greatest changes in science, medicine, and technology in human history. With advancements in human biology, diagnostics, treatments, and AI, we are on the cusp of a new age in healthcare. The question is, how will healthcare systems adapt to this new era and their evolving relationship with industry? Will we continue to patch up the existing legacy paradigm, or is it time for a new vision that addresses the population health challenges of the 21st century? Andy will present a compelling case for a new healthcare paradigm that reflects his work with leaders across the UK health sector. Join us as we delve into the possibilities of a bold new future for healthcare.

Speaker Bio

Andy is a futurist, speaker, podcaster and founder of FUTURE OF HEALTH – a new think tank and systems convener exploring the long term vision for health and healthcare systems in a technology enabled 21st century. He has undertaken numerous healthcare innovation and transformation projects and has authored several high profile reports for the NHS and policy makers on the future of healthcare. Andy is a champion for a new future based on holistic health that includes wrapping person-centred health and care around the needs of individuals and communities and the transformation from silos to new collaborative, multi-sector health ecosystems that will make this possible.



Andy Wilkins
Founder of FUTURE OF HEALTH

KEY NOTE

EUROPEAN HEALTH POLICY: WHAT IS BRUSSEL UP TO?

Abstract

Richard will talk about new proposed EU legislation on secondary use of data (European Health Data Space and the AI Act). He will also cover the pharma package where the final proposal is expected during the Spring, reflect on the role of Health Technology Assessment going forward and finally on the relationship between Switzerland and the EU.

Speaker Bio

Richard Bergström is a pharmacist by training. He received his MScPharm degree from the University of Uppsala, Sweden in 1988 and his honorary doctor title in October 2022. For 10 years he worked in regulatory affairs at global and EU level at Roche and Novartis. For 15 years he was a lobbyist for pharma leading the industry association in Sweden and the in Brussels. During the pandemic he was the vaccine coordinator for the Swedish government and part of the EU Joint Negotiation Team. In September 2022 he joined IQVIA as Vice President European Affairs based in Rotkreuz. He is also a member of the Board of European Health Forum Gastein.



Richard Bergström
Former EFPIA Director General
Vice President European Affairs at IQVIA

EMERGING FROM DISRUPTION: RETHINKING PHARMA

Abstract

Healthcare has faded from the global agenda very quickly. Covid-19 is seemingly a thing of the past. The global cost of over \$12 trillion to the end of 2024 is almost forgotten and is now just a precursor to a world of inflation, war and energy shortages. For healthcare systems, this means not only a shift of focus away from health, but acute economic headwinds putting even more pressure on budgets. This means for the healthcare industry an increasing pressure to demonstrate the benefit of sustainable investments in health and the broader societal value of investing in innovative medicines and solutions. But not all is doom and gloom. There are enormous opportunities coming from the acceleration and combination of data and digitalisation to bring public health level solutions that are better for patients and more cost effective for healthcare systems. There is an openness to private sector partnership like never before - primarily as a result of Covid and a recognition that healthcare needs the private sector - but also from the entrance of new players with the data and digital expertise the public sector does not have. The advance of new technologies and discoveries - as well as innovative combinations of existing ones - have the potential to fundamentally change the way we prevent, diagnose and treat diseases and by doing that significantly contribute to sustainability goals.

IMF calculation till the end of 2024 <https://www.reuters.com/business/imf-sees-cost-covid-pandemic-rising-beyond-125-trillion-estimate-2022-01-20/>

Speaker Bio

Michael Oberreiter is Head of Global Access at Roche, based in Basel. He is an economist by training and completed a post-graduate diploma and master studies in International Politics and Communications. Michael has been involved in the field of health policy, patient access, capacity building and health economics for over 25 years. His experience spans across different therapeutic areas, countries – including Austria, Germany, China and Asia Pacific (APAC) where he was responsible for driving the development of sustainable Policy, Access and System Capacity solutions to strengthen the Healthcare system and improve access to innovative treatments.



Michael Oberreiter
Head of Global Access at Roche


MARKET ACCESS: MOVING FROM AN ADVERSARIAL TO A COLLABORATIVE RELATIONSHIP WITH HEALTHCARE SYSTEMS

Abstract

The pricing relationship between healthcare systems and pharma has all too often been adversarial in nature, but there is now a need for a more collaborative approach. Unusually, emerging markets may offer some lessons for mature markets: companies have long worked individually with healthcare systems and are now forming international coalitions to expedite access. Pharma also has a long tradition of collaboration with academia and is now forging international alliances in fields such as real-world evidence. Governments in Europe are looking to attract investment from life sciences companies, presenting opportunities to reshape the relationship. The UK has gone further than most countries in creating a complete ecosystem for rapid access, though major challenges remain in relation to cost-containment policy. This presentation will explore these themes using specific examples of industry partnerships.

Speaker Bio

Neil Grubert has more than 20 years' experience in pricing, reimbursement, and market access. He spearheaded the development of Decision Resources Group's international market access business, most recently as Vice President of Global Market Access Insights. Since 2014, he has been working as an independent market access consultant, trainer, and writer. His daily posts on global access issues have gained a wide following on LinkedIn, and he is a regular speaker at industry events and company in-house meetings.



Neil Grubert
Independent Global Market Access Consultant, Trainer & Writer

QUO VADIS, ACCES? A PERSPECTIVE FROM REGULATORS AND PAYERS

Abstract

Healthcare systems across the world try to balance financial sustainability with supporting innovations and addressing health inequities. We can observe measures to manage these challenges that impact BioPharma's commercial model and the ability to drive innovations. In the US, the Inflation Reduction Act aims at containing pharma spending, e.g. by renegotiating drug prices under Medicare Part D, which impacts the future commercial model of BioPharma by shortening the de-facto time to annual peak sales post-launch. In Europe, Health Technology Assessments are being harmonized, resulting in uncertainties for drug developers how to demonstrate clinical effectiveness going forward. In parallel, digital solutions are gaining importance and require regulators and payers to standardize reimbursement pathways, though digital health is still regulated by country. These evolutions in access and digital are re-shaping the future R&D as well as commercialization model of BioPharma.

Speaker Bio

Susanne is a partner in the Health, Sciences and Wellness sector, leading EY-Parthenon Strategy in Switzerland. Susanne is focusing on supporting life sciences clients on strategy, strategic partnering, broader access and value, and sustainability. She has ~20 years of experience across the global life sciences and health sectors, having worked at Takeda for six years and at the World Economic Forum, as well as at Booz & Company. Susanne has lived and worked in Europe, the US, the Middle East and South-East Asia.



Susanne Weissbäcker
Partner at EY-Parthenon, Strategy Life Sciences

THE PROMISE OF CELL & GENE THERAPIES – IS THE EUROPEAN HEALTHCARE SYSTEM EQUIPPED TO FAIRLY VALUE AND PAY FOR ONE-TIME, POTENTIALLY CURATIVE TREATMENTS

Abstract

The healthcare industry is at an inflection point with the market now preparing for many cell and gene therapies to be approved over the coming years. A handful of these therapies have been approved to date and are gaining reimbursement whereas others have failed to gain access. What has driven the success and failure of these various cell & gene therapies and what will need to change to ensure sustained investment in research and development of these highly innovative, yet complex therapies? Systems are currently designed to value and pay for chronic and conventional therapies. New innovative outcomes-based and payment approaches are needed, combined with clear guidelines on real-world evidence requirements, to ensure uncertainties about durability of effect and cost can be addressed. Some of the reasons for successes and failures to date, as well as some potential solutions to overcome current barriers to access will be reflected upon.

Speaker Bio

Oswald currently serves as Global Head of Value and Access at Rocket Pharmaceuticals, a clinical-stage biotech, advancing an integrated pipeline of LVV & AAV genetic therapies that correct the root cause of complex and rare life-threatening childhood hematological disorders and cardiomyopathies. He joined Rocket in August 2022. Before Rocket, Oswald was Head of Value and Access EMEA at AveXis/Novartis Gene Therapies that successfully launched Zolgensma, a gene therapy for spinal muscular atrophy (SMA). Earlier Oswald worked in various regional and global marketing and market access roles at Pfizer, Shire, and Alexion. He has 20 years' commercial experience in the pharmaceutical industry with over 10 of those focusing on rare diseases. He holds an LLM in Tax Law from the University of Amsterdam and an MSc in Health Economics, Policy and Management from The London School of Economics and Political Science (LSE).



Oswald Bentinck
VP, Global Head - Value and Access at Rocket Pharmaceuticals

THE PARTNERING MINDSET: AN ESSENTIAL SHIFT TO CREATE MORE SUSTAINABLE HEALTHCARE?

Abstract

How does a partnering mindset translate in the way pharma companies develop innovation, and bring this innovation to patients in the current and future healthcare ecosystem? The Infinity model aimed to achieve what company leaders saw as a 'triple' win in value creation - creating value for patients, for society, and for the company. A true customer-centric approach that Roche was leading to make a difference in rare diseases and even beyond. A conversation with Anne Nijis about the mindset shifts as well as the pitfalls from a real practitioner.

Reference: Mc Kinsey articles: Roche's Infinity Model: Helping to transform the lives of patients with rare diseases July 2021, Developing a customer -centric approach to rare conditions, McKinsey October 22.

Speaker Bio

Anne has an accomplished 30+ year career in the pharmaceutical industry, spanning managing director and vice president roles across top global organisations. Her leadership ethos is deeply influenced by the idea of giving away power rather than hoarding it, to multiply creativity, deepen trust and grow inclusivity – and so enable the emergence of new organisational orders. As a senior leader operating in both developed and emerging markets, Anne is highly skilled at navigating large, complex organisations to deliver lasting change. Her experience in operating in ambiguous and dynamic healthcare systems necessitates dexterity of thinking, adaptability, and determination to see change realised. Anne is a published expert in customer-centric transformation and prior member of the Greek, Ukrainian and the Argentinian Pharma Associations. She is a global citizen, speaks six languages and has lived in eight countries.



Anne Nijis
Transformation Lead Rare Conditions, Roche

DIGITAL HEALTH- FRIEND OR FOE? WHAT ARE WE SCARED OF?

Abstract

With the move to increasingly targeted therapies, the way we involve and partner with patients is shifting strongly to more empowerment and novel & personalized solutions. Digital solutions do have the potential to drive personalized care, connecting multidisciplinary care teams and achieving the outcomes close to what is observed in an clinical trial. At the same time we see many organizations struggling to bring the full value of digital solutions to patients. In this talk we will explore why it is so difficult to make digital elements a sustainable part of care delivery, what internal and external hurdles are slowing digital transformation in healthcare and articulate a perspective on how to potentially overcome them.

Speaker Bio

Chris Easton is a Senior Leader and Global Commercial Franchise Head for Pulmonary Hypertension at Janssen Pharmaceuticals [part of Johnson & Johnson] in Basel; where he leads multiple Global Strategic functions including Marketing, Early Asset Development & Digital Acceleration. He is also the Co-Chair with R&D for the Disease Area Stronghold to ensure all opportunities to transform the treatment paradigm in Pulmonary Hypertension are addressed. Chris has also undertaken numerous international key notes, round table & panel positions, and advisory roles where he shared his passion for transforming patient outcomes and SICKcare to HEALTHcare. He is also a visiting professor at the Lisbon School of Economics & Management, where he gives a lecture titled Mission: Patient Centricity.



Chris Easton
Disease Area Stronghold Global Commercial Leader, Pulmonary Hypertension at Johnson & Johnson (Janssen Pharmaceuticals)

KEY NOTE

THE SUSTAINABILITY OF BIOPHARMA R&D PRODUCTIVITY: IS 2023 THE “PERFECT STORM”?

Abstract

Declining R&D productivity is back in the spotlight. Biopharma business models are characterized by lengthy timelines and voracious capital needs—characteristics that make them exquisitely sensitive to today’s rising rates and declining capital availability. Low interest rates and Covid-era subsidies hid the problem temporarily, but it’s back with a vengeance. Meanwhile, political pressure on drug pricing is also rising: For the first time, the U.S. government has started imposing price caps on new drugs (Inflation Reduction Act). Given these pressures, our industry must somehow find a way back to its more profitable and sustainable heyday. Model-based analysis is one way to develop fresh insights into these intractable-seeming problems, and reveal which solutions would have the most positive impact.

Speaker Bio

Brian Finrow is CEO and co-founder of Lumen Bioscience, a Seattle-based, clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases. Lumen’s unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale, and exponentially lower costs than current approaches. Brian started his career practicing law out of Harvard Law School as a corporate lawyer representing biotech companies for 10 years, his entry into the industry.



Brian Finrow
CEO and co-founder of Lumen Bioscience

GOOD PARTNERING PRACTICES

The Good Partnering Practices are a set of principles that provide a best practice framework for Business Development and Licensing. They are presented on the Swiss HLG website as a series of ScENIC chapters in clear and appealing cartoon and booklet formats.

- **S**couting & Prospecting
- **E**valuation & Due Diligence
- **N**egotiation & Execution
- **I**ntegration & Alliance Management
- **C**onflict Resolution & Termination

A shared understanding of commonly accepted principles, terms and processes helps build empathy and trust in the dealmaking environment. This facilitates transparent interactions, avoids misunderstandings, and promotes successful partnerships.

www.swisshlg.com

SCAN THE QR CODE TO VIEW THE GPP BOOKLET



AN INITIATIVE OF SWISS HLG

CURRENT TRENDS IN LIFE SCIENCE/PHARMACEUTICAL INDUSTRY SUPPLY CHAIN... ARE CHANGES ACCELERATING IN MANUFACTURING?

Abstract

In this presentation I will focus on the main developments observed are in the Pharma industry manufacturing specifically from geopolitical, commercial social and environmental standpoints.

- I will focus on evolution of those areas the recent past, present time and in years to come
- What is the magnitude of changes in those areas?
- What are their likely impacts on the Pharma landscape in years to come

How are Pharma players adapting to changes occurring? responding to those? triggering those? Following those?

Practical illustrations, experiences from some main players on markets will be shared. How much are different players likely or prepared to invest in those changes? Finally What value will come out of those changes for Pharma players and patients?

Speaker Bio

Jean Vielle is Global Head Integration/Separation at Novartis Pharma AG Roche based in Basel, Switzerland. In this role, he has responsibility for structuring and negotiating acquisition and sale agreements for assets and technologies. At Novartis for 21 years, Jean started prior to his current role in technical Project management to then work on divestments, Pharma Operations strategy, Procurement, CMO management. Jean joined Novartis from major chemical and consulting companies. He graduated in science and then studied in business and administration.



Jean Vielle
Global Head Integration Separation, Novartis AG

THE GLOBAL FIGHT AGAINST THE BIG PANDEMICS: A CASE STUDY ON PARTNERSHIPS, SUSTAINABILITY AND INNOVATION

Abstract

The global response against HIV-Aids, Tuberculosis and Malaria has shown remarkable progress over the last two decades. Concerted efforts between international partners, governments, private sector and civil society, have allowed unprecedented investments, saving millions of lives and introducing new treatments, diagnostics and medical devices to the market. Despite the disruptions caused by the COVID-19 and other challenges such as antimicrobial resistance and competing funding priorities, the world is getting back on track towards ending the big pandemics. How can the global fight continue progressing and innovating? What strategic elements could be adjusted to collaborate more efficiently, and to enhance the market's opportunities? In this session I will discuss the success factors and potential areas of optimization to raise the partners' game, with a specific focus on the role of the industry.

Speaker Bio

Lelio Marmora is an international development leader with more than 30 years of experience overseeing public and private large-scale investments in more than 120 countries. He served as Executive Director of Unitaid in Geneva, Switzerland, from 2014 to 2020, overseeing a \$2B portfolio of investments in global health innovation. Prior to that, he worked 8 years at the Global Fund to Fight AIDS, TB and Malaria, first in charge of the Latin America and the Caribbean region, and then as Director for Africa and the Middle East (\$8+B portfolios). Earlier in his career, Lelio served in various capacities at a range of international organizations, including the World Bank, the Inter American Development Bank and several United Nations agencies. Lelio is the CEO of The Management Lab, a consulting firm based in Geneva, Switzerland, specialized in international development public/private large-scale investments. He is also a member of the Board of Directors at Orasure Technologies Inc. (NASDAQ: OSUR), a Board Member of the MTV Foundation, and is also a founding member of the Think Tank Santé Mondiale 2030 in Paris, France. Lelio is the recipient of several national Orders and national/international awards. Alma Mater: Université Panthéon-Assas (Paris II) - Paris, France.



Lelio Marmora
CEO at The Management Lab

CLOSING KEY NOTE

**SUSTAINABILITY IN THE BIOPHARMA INDUSTRY:
HOW PARTNERSHIPS CAN DRIVE IMPACT****Abstract**

Despite tangible improvements in human health outcomes over the last three decades, fundamental challenges remain in the field of healthcare. In a fragmented post-pandemic world, the biopharma industry faces the strain of ageing populations, over-stretched health systems and notably, the growing dual burden of communicable and non-communicable diseases in low-to-middle income countries. These health challenges are coupled with the rising societal demand for sustainability across different healthcare business practices and dimensions. Dr. Lutz Hegemann will provide an overview on what biopharma sustainability looks like, including the areas in which pharmaceutical companies can create the greatest impact, and the pivotal role that partnerships can play in driving this.

Speaker Bio

Lutz Hegemann leads the Novartis Global Health unit and is responsible for integrating environmental, social and governance (ESG) matters into the core of the company's business, with a special emphasis on innovation and access. Before taking on his present role, Lutz was Group Head of Corporate Affairs and Global Health. He has held roles of increasing responsibility since joining Novartis in 2005 in the Consumer Health Division. He began his career as a public health physician and scientist. Lutz is a Fellow of the Royal Society for Tropical Medicine & Hygiene and serves on the boards of the Novartis Foundation, the Swiss Alliance against Neglected Tropical Diseases, the Tanzania Training Centre of International Health, PATH, and the Swiss Tropical and Public Health Institute.



Lutz Hegemann
President Global Health & Sustainability at Novartis

NOTES

NOTES

NOTES

NOTES

JOIN US! BE PART OF A CIRCLE OF PASSIONATE, BUSINESS DEVELOPMENT EXECUTIVES.

- Focused and effective networking with senior level peers
- Opportunity to contribute to events, the Start-up Initiative, Good Partnering Practices (GPP) and other activities
- Education among peers and dissemination of GPPs
- Membership of our LinkedIn community
- Access to the unique PLG/HLG European database, encompassing members of an international network of 10 healthcare licensing groups
- Special rates and discounts to Swiss HLG & PLG /HLG joint events
- Increased visibility of your organization

More info at www.swisshlg.com

SAVE THE DATE

IPLS AMSTERDAM – FUTURE LIFE CYCLES
TUESDAY 19 – THURSDAY 21 SEPTEMBER 2023

SUBSCRIBE TO OUR NEWSLETTER AND LINKEDIN
TO KEEP UP TO DATE ON SWISS HLG EVENTS



Swiss Healthcare Licensing Group
St.-Jakobs-Strasse 7
Postfach 2879
4002 Basel
Switzerland

info@swisshlg.com
www.swisshlg.com